Clinical and Economic Consequences of Nonadherence to IV Iron

Panelists discuss how nonadherence to IV iron therapy can lead to persistent anemia, worsening symptoms, increased health care utilization and costs, and diminished quality of life, with patients experiencing continued fatigue, reduced work productivity, and increased risk of complications from their underlying conditions.

EP: 1.Background and Causes of Iron Deficiency Anemia

EP: 2.Pathophysiology of Iron Deficiency Anemia

EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia

EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia

EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis

EP: 6.Oral vs IV Iron in Clinical Practice

EP: 7.FDA-Approved IV Iron Formulations

EP: 8.Factoring in Safety Considerations With IV Iron Products

EP: 9.Adverse Effects Associated With Hypophosphatemia

EP: 10.Clinical Impact of Hypophosphatemia

Now Viewing

EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron

EP: 12.Adherence and Time Spent Receiving IV Iron Infusions

EP: 13.Step Edits Associated with IV Iron Therapies

EP: 14.The Future of IV Iron Administration

EP: 15.Closing Thoughts on Iron Deficiency Anemia

Video content above is prompted by the following:

• What are the potential clinical and economic consequences of nonadherence to IV iron therapy?
• How does nonadherence to therapy decrease patient quality of life?

Related Videos

Related Content

Advertisement

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 16th 2025

Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer

Brooke McCormick

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported by data from the POD1UM-303/InterAACT2 and POD1UM-202 trials.

May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

Ofer Kobo, MD Martin K. Rutter, MD Shivani Misra, PhD Erin D. Michos, MD, MHS Phyo K. Myint, MD Ariel Roguin, MD, PhD Louise Y. Sun, MD Mamas A. Mamas, MD

This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.

Related Content

Advertisement

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 16th 2025

Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer

Brooke McCormick

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported by data from the POD1UM-303/InterAACT2 and POD1UM-202 trials.

May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

Ofer Kobo, MD Martin K. Rutter, MD Shivani Misra, PhD Erin D. Michos, MD, MHS Phyo K. Myint, MD Ariel Roguin, MD, PhD Louise Y. Sun, MD Mamas A. Mamas, MD

This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.